# Critical Analysis: p300/CBP Inhibitors for AD/TBI Prevention
## Foundational Validity Assessment
Before evaluating mechanistic hypotheses, the field must confront an uncomfortable truth: **the dual clinical benefit premise is unestablished for clinically diagnosed TBI**.
### What Exists vs. What's Claimed
| Claim | Evidence Status | Source |
|-------|----------------|--------|
| Salsalate reduces Aβ/p-tau in CSF | **Established** (Phase 2 TIA trial) | NCT00513262 |
| Salsalate improves cognition in AD | **Moderate** (trend, not primary endpoint) | PMID: 29104224 |
| p300 inhibitors reduce Aβ pathology | **Preclinical only** | Multiple mouse studies |
| Salsalate/p300i reduces TBI *incidence* | **NOT ESTABLISHED** | No clinical trials with TBI as outcome |
**The mechanistic hypotheses are building on sand.** This isn't a minor gap—TBI incidence prevention is a fundamentally different endpoint than biomarker modulation or cognitive improvement. Epidemiological aspirin studies (which share salicylate moieties) have not consistently shown reduced TBI rates.
---
## Drug/Target Landscape Analysis
### 1. p300/CBP (EP300/CREBBP) as Drug Targets
**Druggability Assessment: MODERATE-HIGH for bromodomain inhibitors, LOW for catalytic inhibitors**
**Tool Compounds & Clinical Candidates:**
| Compound | Company | Status | Key Limitation |
|----------|---------|--------|----------------|
| **A-485** | AbbVie/AcetylCoA | Research tool, discontinued | Poor solubility, PK issues |
| **CCS1477 (ABBV-222)** | AbbVie/CellCentric | Phase 1/2 (prostate cancer) | Prostate cancer indication only |
| **ICBP112** | Academic | Research tool | Low potency |
| **Boc5** | Academic | Discredited | Later disputed |
**Critical Issue:** Salsalate/diflunisal are **NOT selective p300/CBP inhibitors**. They inhibit p300/CBP only at concentrations far above human therapeutic levels. Their primary mechanisms are:
- COX-1/COX-2 inhibition (anti-inflammatory)
- IKKβ/NF-κB inhibition
- AMPK activation
- Mitochondrial uncoupling at high doses
Attributing salsalate's effects specifically to p300/CBP inhibition requires demonstration that selective p300 inhibitors (A-485, CCS1477) produce identical effects. This comparison **has not been done** in neurodegeneration models.
**Competitive Landscape:** p300/CBP inhibitors are actively pursued for oncology, not neurodegeneration. No clinical trials for AD indication.
---
### 2. Nrf2 (NFE2L2) Pathway
**Druggability: HIGH (indirect via Keap1)**
**Existing Compounds:**
| Compound | Mechanism | Status | AD Connection |
|----------|-----------|--------|----------------|
| **Bardoxolone methyl** | Keap1/Nrf2 activator | Failed (BEACON trial), discontinued | Cardiovascular mortality concerns |
| **Dimethyl fumarate (Tecfidera)** | Nrf2 activator | Approved (MS) | Off-label AD trials ongoing |
| **Sulforaphane** | Nrf2 activator | Dietary supplement | No clinical AD trials |
| **Oltiveloxolone (Skyclarys)** | Nrf2 activator | Approved (Friedreich's ataxia) | — |
**Key Issue:** Bardoxolone methyl failed catastrophically in diabetic kidney disease (BEACON trial, NCT01351675) due to cardiovascular mortality, raising red flags for any Nrf2 activator used chronically in elderly populations. The therapeutic window concern I raised in the skeptic section is not theoretical—it's demonstrated in a large Phase 3 trial.
**AD Clinical Trials:** None of these have robust AD efficacy data. Dimethyl fumarate has mechanistic rationale but clinical evidence is lacking.
---
### 3. ACAT1 (SOAT1) Pathway
**Druggability: HIGH**
**Clinical History: FAILED**
| Compound | Indication | Trial | Outcome |
|----------|------------|-------|---------|
| **Avasimibe** | Atherosclerosis | NCT00770176 | Discontinued—limited efficacy |
| **Pactimibe** | Atherosclerosis/AD | Multiple | Failed—no CNS benefit |
| **CI-1011** | Atherosclerosis | NCT00138203 | Failed |
**The hypothesis relies on failed drugs.** If ACAT1 inhibition prevented AD, this would have been demonstrated in the avasimibe/pactimibe programs. These compounds *did* inhibit ACAT1 and *did* reach clinical trials—they simply didn't work for neurodegeneration.
**Timeline for validation:** 5-7 years minimum (new ACAT1-selective compounds with improved brain penetration would need full AD development).
---
### 4. FOXO1 as Target
**Druggability: LOW (transcription factor)**
**Current approach:** No direct FOXO1 inhibitors exist. Research focuses on:
- Upstream: AKT activators (none in clinic), PI3K modulators
- Indirect: SGLT2 inhibitors (empagliflozin) may activate FOXO via AMPK
**Issue:** FOXO1 acetylation is a fine-tuning mechanism. The net effect of blocking FOXO1 acetylation in neurons (where FOXO has context-dependent protective and harmful effects) is **unpredictable**. The hypothesis requires demonstrating necessity AND sufficiency—neither has been shown.
---
### 5. GR (NR3C1) as Target
**Druggability: HIGH**
**Clinical History: COMPLEX**
| Drug | Status | AD Connection |
|------|--------|----------------|
| **Mifepristone (RU-486)** | Approved (Cushing's) | Limited cognitive benefit in trials |
| **Relacorilant (CORT125134)** | Phase 2 (Cushing's) | — |
**Critical failure:** Mifepristone trials for AD-associated cognitive dysfunction showed marginal benefit at best. If GR antagonism prevented AD, this would have translated. The disconnect between the proposed mechanism and clinical reality is significant.
---
### 6. Ankyrin-G / BMAL1
**Druggability: VERY LOW**
Neither target is considered druggable:
- Ankyrin-G is a large (~1900 aa) membrane-associated scaffolding protein
- BMAL1/CLOCK are transcription factors with limited small-molecule tractability
Research tools exist (shRNA, CRISPR) but therapeutic application is distant.
---
## Safety Considerations
| Compound Class | Key Safety Concerns | Implications for Chronic AD Prevention |
|----------------|---------------------|----------------------------------------|
| **p300/CBP inhibitors** | Unknown (no chronic dosing data in elderly) | p300 is essential for cardiac development; cardiac toxicity possible |
| **Nrf2 activators** | Cardiovascular mortality (bardoxolone), LFT abnormalities | May increase mortality in frail elderly populations |
| **ACAT1 inhibitors** | Liver toxicity (observed in trials) | Acceptable for short-term, unacceptable for years of prevention |
| **GR antagonists** | Adrenal insufficiency, hepatic effects | Requires careful monitoring, contraindications in many elderly |
| **Salsalate itself** | GI bleeding, tinnitus, renal | Well-characterized, manageable but not trivial |
**The chronic prevention problem:** All hypotheses require years of treatment in otherwise healthy (or mildly impaired) elderly individuals. Safety profiles acceptable for acute use (TBI) or serious disease (Cushing's) may be unacceptable for prevention.
---
## Timeline & Cost Estimation
| Stage | Duration | Estimated Cost | Key Uncertainties |
|-------|----------|----------------|-------------------|
| Preclinical validation (key mechanism) | 2-3 years | $3-5M | Which mechanism is actually engaged? |
| Biomarker studies in existing cohorts | 1-2 years | $1-2M | CSF/imaging biomarkers for pathway engagement |
| Phase 2a (mechanistic, n=50-100) | 2 years | $5-10M | TBI incidence not practical endpoint |
| Phase 2b/3 for AD (cognitive endpoint) | 4-6 years | $50-100M+ | Requires 1000+ subjects, years of treatment |
| Phase trial with TBI incidence | **Not feasible** | Would require 10,000+ subjects, decades | Event rate too low for practical trial |
**The TBI endpoint problem is insurmountable for a drug development program.** With ~300-400 TBI hospitalizations per 100,000 person-years in elderly, demonstrating a 20% reduction would require:
- ~20,000 participants followed for 5 years
- Cost: $200-500M
- Time: 8-10 years
No sponsor would pursue this. Therefore, the "TBI prevention" hypothesis will never be clinically validated.
---
## Revised Confidence with Drug Development Reality
| Hypothesis | Revised | Primary Limitation |
|------------|---------|---------------------|
| Nrf2 | **0.42** | Bardoxolone failure, chronic safety |
| CAA | **0.35** | Incidence vs. severity confusion |
| Insulin/FOXO1 | **0.32** | Undruggable target, brain/peripheral conflation |
| ACAT1 | **0.28** | Failed drug class |
| Circadian | **0.25** | Salsalate doesn't affect circadian rhythms |
| Ankyrin-G | **0.22** | Undruggable, causal direction unproven |
| GR | **0.21** | Mifepristone trials were negative |
---
## Most Practical Path Forward
**Given drug development realities, what can actually be tested?**
1. **Is salsalate's effect on AD biomarkers p300/CBP-dependent?**
- Compare salsalate vs. A-485 in human neurons/iPSC-derived neurons
- CRISPRi of p300 vs. non-p300 salsalate targets
- **Cost:** $200-500K, 12-18 months
2. **Does selective p300 inhibition (CCS1477) replicate salsalate's effects in AD models?**
- Use CCS1477 (in clinical development, available for research) in 3xTg-AD mice
- **Cost:** $300K, 18 months
3. **Is Nrf2 activation necessary and sufficient?**
- Nrf2 KO mice + salsalate (as critic suggests)
- Keap1 KO mice (constitutive Nrf2) - do they show same phenotype?
- **Cost:** $150K, 12 months
4. **TBI endpoint isn't tractable—but TBI *severity* might be:**
- Retrospective analysis of trauma cohorts with prior salicylate exposure
- Post-hoc from existing Phase 3 salsalate trials
- **Cost:** Low, but evidence level is low
---
## Bottom Line
The hypotheses are scientifically creative but face **four fatal problems:**
1. **Premise problem:** TBI incidence reduction by p300 inhibitors is not established
2. **Selectivity problem:** Salsalate ≠ p300 inhibitor; the mechanism is almost certainly multi-target
3. **Druggability problem:** Several key targets (FOXO1, Ankyrin-G, BMAL1) are not druggable
4. **Clinical tractability problem:** The TBI endpoint cannot be pursued in drug development
**The most honest assessment:** Salsalate may have modest benefit for AD (as the TIA trial suggests). Mechanistic hypotheses should focus on what's actually druggable (Nrf2, potentially via dimethyl fumarate which is already in trials) rather than requiring specific molecular mechanisms that don't translate to clinical candidates.